ArticleBlood2009
Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases.
Article in Blood, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 227 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
227 citing papers in PubMed, 2 syntheses or guidelines pooled it, 702 citations in OpenAlex.
- Rare COVID-19 vaccine side effects got lost in the shuffle. Primary cutaneous lymphomas following COVID-19 vaccination: a systematic review.Frontiers in medicine · 2024Pooled it
- Interventions for mycosis fungoides.The Cochrane database of systematic reviews · 2020Pooled it
- Trial
- Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution.Annals of oncology : official journal of the European Society for Medical Oncology · 2015Trial
- TG1042 (Adenovirus-interferon-γ) in primary cutaneous B-cell lymphomas: a phase II clinical trial.PloS one · 2014Trial
- Clinical in-vivo dosimetry for total skin electron therapy using gafchromic™ EBT4 film.Journal of applied clinical medical physics · 2026Article
- Targeting the G-protein-coupled estrogen receptor: a novel therapeutic strategy in cutaneous T-cell lymphoma.Blood neoplasia · 2026Article
- Cutaneous T-cell lymphoma in Kuwait: a retrospective analysis of treatment modalities and prognostic factors.International journal of hematology · 2026Article
- Mycosis Fungoides Is a Proliferation of Multiple Mutational Subclones.The Journal of dermatology · 2026Review
- Recent trends of incidence and mortality of cutaneous lymphomas in Germany.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Article
- Clinical and Prognostic Features of Erythrodermic Cutaneous T-Cell Lymphoma: A Retrospective Study of 35 PatientsTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026Article
- Clinical and Pathological Characteristics of Skin Cancer Patients at Southern Medical University, Guangzhou, China.Acta dermato-venereologica · 2026Article
- Clinical Implications of the Skin Microbiota in the Therapy of Cutaneous T Cell Lymphoma: A Scoping Review.Dermatology and therapy · 2026Review
- Primary Cutaneous B-Cell Lymphomas: An Updated Portrait of Classification, Biology, and Clinical Management.European journal of haematology · 2026Review
- Incidence and Mortality of Mycosis Fungoides and Sezary Syndrome: A Nationwide Registry Study in Finland.Acta dermato-venereologica · 2026Article
- COVID vaccination and post-infection cancer signals: Evaluating patterns and potential biological mechanisms.Oncotarget · 2026Review
- Secondary cutaneous marginal zone lymphoma arising in association with a Mohs micrographic surgery graft site.JAAD case reports · 2026Article
- Prognostic factors in Sézary syndrome - a retrospective propensity score-matched study on 1277 patients.Frontiers in immunology · 2026Article
- Acalabrutinib treatment in relapsed/refractory primary cutaneous diffuse large B cell lymphoma, leg type. Case report.Frontiers in oncology · 2026Article
- Beyond the Rash: Cutaneous Peripheral T-Cell Lymphoma as a Diagnostic Pitfall in Primary Care.Cureus · 2026Article
167 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
There have been no prior large population-based studies focusing on cutaneous lymphomas (CL) in the United States. Using the Surveillance, Epidemiology and End Results (SEER) program data, we analyzed age-adjusted CL incidence rates (IRs) and survival rates by sex and race/ethnicity. There were 3884 CLs diagnosed during 2001-2005. Cutaneous T-cell lymphomas (CTCLs) accounted for 71% (age-adjusted incidence rate [IR] = 7.7/1 000 000 person-years), whereas cutaneous B-cell lymphomas(CBCLs) accounted for 29% (IR = 3.1/1 000 000 person-years). Males had a statistically significant higher IR of CL than females (14.0 vs 8.2/1 000 000 person-years, respectively; male-female IR ratio [M/F IRR] = 1.72; P < .001). CL IRs were highest among blacks and non-Hispanic whites (both 11.5/1 000 000 person-years), followed by Hispanic whites (7.9) and Asian/Pacific Islanders (7.1). The CTCL IR was highest among blacks (10.0/1 000 000 person-years), whereas the CBCL IR was highest among non-Hispanic whites (3.5). Over the past 25 years, the CL IR increased from 5.0/1 000 000 person-years during 1980-1982 to 14.3 during 2001-2003. During 2004-2005, the CL IR was 12.7. This recent apparent change could be incomplete case ascertainment or potential leveling off of IRs. CLs rates vary markedly by race and sex, supporting the notion that they represent distinct disease entities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.